Yahui Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yahui Cao has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ronglan Zhao
School of Medical Laboratory, Shandong Second Medical University, Weifang, China
2 shared publications - Xiaoxiang Peng
School of Medical Laboratory, Shandong Second Medical University, Weifang, China
2 shared publications - Yanan Du
School of Medical Laboratory, Shandong Second Medical University, Weifang, China
2 shared publications - Geng Xu
Department of Thoracic Surgery, Heze Municipal Hospital, Heze, 274031, Shandong, China
1 shared publication - Meng Yan
School of Medical Laboratory, Shandong Second Medical University, Weifang, China
1 shared publication Qingqing Yu
School of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China
1 shared publication
Latest Publications
- 22 August 2025
- Published by Springer Nature in Purinergic Signalling
- Vol. 21 (6) , 1249-1260
The P2X7 receptor in leukemia: pathological mechanisms and therapeutic potential
The P2X7 receptor is a trimeric ion channel purinergic receptor. It plays a crucial part in the pathophysiology of cancers and a variety of inflammatory diseases and is widely expressed in different cell types. Leukemia represents a type of malignant clonal disorder that impacts the hematopoietic stem cells. Chemotherapy is one of the main treatment methods for leukemia, but there are also many side effects. In recent years, targeted therapy is a new treatment method. Research has shown that the progression and occurrence of leukemia is significantly related to the P2X7 receptor. The P2X7 receptor is also involved in the migration and invasion of leukemia cells. Furthermore, the polymorphism of the P2X7 receptor gene also takes on a significant function in the occurrence, development and clinical course of leukemia patients. The P2X7 receptor inhibitors have been found to work better in combination with existing therapeutics. Therefore, the P2X7 receptor may serve as a potential therapeutic target.
- 22 August 2025
- Published by Springer Nature in Purinergic Signalling
- Vol. 21 (6) , 1249-1260
The P2X7 receptor in leukemia: pathological mechanisms and therapeutic potential
The P2X7 receptor is a trimeric ion channel purinergic receptor. It plays a crucial part in the pathophysiology of cancers and a variety of inflammatory diseases and is widely expressed in different cell types. Leukemia represents a type of malignant clonal disorder that impacts the hematopoietic stem cells. Chemotherapy is one of the main treatment methods for leukemia, but there are also many side effects. In recent years, targeted therapy is a new treatment method. Research has shown that the progression and occurrence of leukemia is significantly related to the P2X7 receptor. The P2X7 receptor is also involved in the migration and invasion of leukemia cells. Furthermore, the polymorphism of the P2X7 receptor gene also takes on a significant function in the occurrence, development and clinical course of leukemia patients. The P2X7 receptor inhibitors have been found to work better in combination with existing therapeutics. Therefore, the P2X7 receptor may serve as a potential therapeutic target.
- 22 February 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 995, 177421
Overexpression or knockdown of the P2X7 receptor regulates the progression of non-small cell lung cancer, involving GSK-3β and JNK signaling pathways
- 22 February 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 995, 177421
Overexpression or knockdown of the P2X7 receptor regulates the progression of non-small cell lung cancer, involving GSK-3β and JNK signaling pathways